PTGS2 and glioblastoma: According to our knowledge, this is the first evidence that the treatment with a COX-2 inhibitor leads to increased chemosensitivity to TMZ in GBM cells through a down-regulation of the overexpression of COX-2 levels, as well as through activity induced by the drug.